Found 22 matching trials
Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder PHASE2 The primary objective of this study is to evaluate the efficacy and tolerab...
Show More Learn More & Join Trial
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment PHASE3 The study will evaluate the antipsychotic efficacy of ITI-007 in a randomiz...
Show More Learn More & Join Trial
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression PHASE3 The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) i...
Show More Learn More & Join Trial
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia PHASE4 The main question this study is trying to answer is whether lumateperone, a...
Show More Location
UMass Chan Medical School
Learn More & Join Trial
Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse PHASE4 The purpose of this clinical research study is to understand how effective ...
Show More Location
Health Discovery Building
Learn More & Join Trial
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder PHASE1 Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, t...
Show More Location
Collaborative Neuroscience Research, LLC
Learn More & Join Trial
Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression PHASE3 The study will evaluate the efficacy and safety of ITI-007 adjunctive to li...
Show More Learn More & Join Trial
Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia PHASE2 The purpose of this study is to determine the relationship between ITI-007 ...
Show More Location
Johns Hopkins Medical Institutions
Learn More & Join Trial
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder PHASE3 This is a multicenter, open-label, fixed dose, 26 week study of patients wi...
Show More Learn More & Join Trial
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. PHASE3 This study is looking to determine if Lumateperone improves motivation in p...
Show More Location
LSU Health Shreveport
Learn More & Join Trial